Yixintang Pharmaceutical Group Co., Ltd. (SHE:002727)
China flag China · Delayed Price · Currency is CNY
12.97
+0.39 (3.10%)
Oct 29, 2026, 3:00 PM CST

SHE:002727 Balance Sheet

Millions CNY. Fiscal year is Jan - Dec.

Assets

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Cash & Equivalents
2,8542,3023,4183,6763,5122,235
Short-Term Investments
---219.66--
Trading Asset Securities
685.88759.84--8.36297.3
Cash & Short-Term Investments
3,5403,0623,4183,8953,5202,532
Cash Growth
10.72%-10.40%-12.26%10.66%39.00%-17.16%
Accounts Receivable
1,4891,5631,6131,5551,7761,376
Other Receivables
263.09312.22319.49313.3307.29206.63
Receivables
1,7521,8751,9321,8682,0831,583
Inventory
3,3613,6734,0883,8533,3873,317
Prepaid Expenses
-1.033.491.030.140.16
Other Current Assets
623.64335.68270.29275.63467.06260.12
Total Current Assets
9,2778,9479,7129,8939,4587,692
Property, Plant & Equipment
3,1583,5743,9563,9513,9944,080
Long-Term Investments
141.48131.4136.52143.26352.46107.22
Goodwill
1,9781,9611,9831,6501,3971,380
Other Intangible Assets
290.86277.08196.86178.08165.67122.89
Long-Term Deferred Tax Assets
98.37102.0493.788.9494.1158.46
Long-Term Deferred Charges
464.26556.44724.03661.17629.9590.75
Other Long-Term Assets
43.5158.692982.3188.59305.71
Total Assets
15,45115,60816,83016,64716,17914,337

Liabilities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Accounts Payable
4,4204,4364,9164,3394,3293,806
Accrued Expenses
240.29460.29539.54681.48518.75295.38
Short-Term Debt
577.67538.78503.76468.6402.57127.7
Current Portion of Long-Term Debt
816.39--1.80.24.02
Current Portion of Leases
-8511,005975.88932.771,012
Current Income Taxes Payable
178.0556.5653.6281.37197.86118.4
Current Unearned Revenue
155.34110.6116.9113.72156.61105.18
Other Current Liabilities
546.5411.2496.42537.55339.23415.09
Total Current Liabilities
6,9346,8647,6317,2006,8775,884
Long-Term Debt
5.8---1.835.08
Long-Term Leases
869.861,2661,5311,5521,7571,729
Long-Term Unearned Revenue
26.0816.2911.5514.5412.1513.34
Long-Term Deferred Tax Liabilities
3.113.33.553.934.053.56
Total Liabilities
7,8398,1509,1778,7708,6527,665

Shareholders' Equity

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Common Stock
585.6585.6585.6596.01596.02596.18
Additional Paid-In Capital
2,0122,0132,0192,1442,1472,157
Retained Earnings
5,0144,8634,8865,0114,7003,869
Treasury Stock
-150-150--4.24-22.69-46.86
Comprehensive Income & Other
-7.98-8.55--6.192.93
Total Common Equity
7,4547,3037,4917,7467,4266,578
Minority Interest
157.39153.84162.27131.04101.4494.8
Shareholders' Equity
7,6127,4577,6537,8777,5286,673
Total Liabilities & Equity
15,45115,60816,83016,64716,17914,337

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Total Debt
2,2702,6563,0392,9983,0942,908
Net Cash (Debt)
1,270406.14378.39896.84425.94-375.58
Net Cash Growth
234.38%7.34%-57.81%110.56%--
Net Cash Per Share
2.240.700.641.500.72-0.63
Filing Date Shares Outstanding
574.34574.13585.6596.01596.02596.18
Total Common Shares Outstanding
574.34574.13585.6596.01596.02596.18
Working Capital
2,3422,0822,0802,6932,5811,809
Book Value Per Share
12.9812.7212.7913.0012.4611.03
Tangible Book Value
5,1855,0655,3115,9185,8635,075
Tangible Book Value Per Share
9.038.829.079.939.848.51
Buildings
-916.42892.7894.92785.07741.03
Machinery
-465.66447.47416.9385.35350.85
Construction In Progress
-165.235.799.813.8725.47